Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: Results from the DISCOVER studies

Annals of Clinical Microbiology and Antimicrobials

Volumn 14, Issue 1, 2015, Pages

  Dunne, Michael W ^a   Sahm, Dan ^b   Puttagunta, Sailaja ^a  

^a Durata Therapeutics   (United States)

^b International Health Care Associates Inc   (United States)

Author keywords

Acute bacterial skin and skin structure infections; Antimicrobial agents; Dalbavancin; Susceptibility testing; Vancomycin

Indexed keywords

DALBAVANCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; TEICOPLANIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CONCENTRATION RESPONSE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PREDICTION; SKIN STRUCTURE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS DYSGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; HUMAN; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; STAPHYLOCOCCAL INFECTIONS;

ADULT; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN;

EID: 84926376165     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/s12941-015-0081-5     Document Type: Article

References (10)

1. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. NEJM. 2014;370(23):2169-78.
2. DalvanceTM Package Insert 2014. DurataTherapeutics Intl., Chicago, IL, USA. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021883s000lbl.pdf. Accessed July 2014
3. Clinical and Laboratory Standards Institute. M100-S24. Performance standards for antimicrobial susceptibility testing: 24th informational supplement. Wayne, PA: CLSI; 2014.
4. Friedland IR, Isaacs R, Mixson LA, Motyl M, Woods GL. Use of surrogate antimicrobial agents to predict susceptibility to ertapenem. Diagn Microbiol Infect Dis. 2002;43:61-4.
5. Jones RN, Sader HS, Fritsche TR, Hogan PA, Sheehan DJ. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J Clin Microbiol. 2006;44:2622-5.
6. Jones RN, Farrell DJ, Flamm RK, Sader HS, Dunne MW, Mendes RE. Surrogate Analysis of Vancomycin to Predict Susceptible Categorization of Dalbavancin. Diagn Microbiol Infect Dis. 2015 Published online Feb 7. doi:10.1016/j.diagmicrobio.2015.01.017.
7. CLSI M100-S24. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. 2014, 34: 1.
8. Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial. Surveillance Program (2011). 2013;75:304-7.
9. Kronvall G, Kahlmeter G, Myhre E, Galas MF. A new method for normalized interpretation of antimicrobial resistance from disk test results for comparative purposes. Clin Microbiol Infect. 2003;9:120-32.
10. Kahlmeter G, EUCAST. ECOFF presentation to clinical laboratory and standards institute meeting. Tampa, FL USA: EUCAST; 2013.